Compare Levi Strauss & Co. (LEVI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Medpace Holdings Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 3.36% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Medpace Holdings Inc for 14 Days on average.
| LEVI | MEDP | |
|---|---|---|
Market Cap | $7.31B | $16.82B |
Volume | 13,683,095 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $630.19 |
52-Week Low | $17.92 | $393.42 |
Typical Hold Time | 70 Days | 14 Days |
Enterprise Value | $8.86B | $16.44B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for four consecutive quarters, including Q3 2026 EPS of $0.48 versus $0.36 expected. Financial health is robust with a net income margin of 8.83% and ROE of 25.76%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 results driven by denim demand trends.
The investment outlook is positive based on fundamentals and analyst sentiment, with a consensus price target of $29.00 implying significant upside. Risks include competitive pressures, recent cybersecurity incidents, and macroeconomic sensitivity. Wall Street maintains a strong buy consensus, supporting a favorable risk-reward profile for long-term investors.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
